Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Forest And Eisai Cut Drug R&D Jobs

by Lisa M. Jarvis
December 9, 2013 | A version of this story appeared in Volume 91, Issue 49

Forest Laboratories is cutting 500 jobs, about 9% of its workforce, as part of an overhaul of its business a year after losing patent protection on its top-selling drug, the antidepressant Lexapro. The goal is to trim $500 million in annual expenses by the end of 2016. Revamping R&D will account for $270 million of the savings, while changes to Forest’s marketing operation will add another $150 million. Meanwhile, Japanese drugmaker Eisai is also streamlining its research and clinical operations in moves that will cost 130 jobs in the U.S. and Europe. Eisai appears to be joining many of its big pharma competitors in a retrenchment from internal neuroscience research. The company said it will end medicinal chemistry activities in England to focus on an open innovation neuroscience drug discovery venture with University College London.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.